ChromaDex Yönetim

Yönetim kriter kontrolleri 4/4

ChromaDex CEO'su Rob Fried, Jun2018 tarihinde atandı, in görev süresi 6.42 yıldır. in toplam yıllık tazminatı $ 1.16M olup, şirket hissesi ve opsiyonları dahil olmak üzere 43.1% maaş ve 56.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.06% ine doğrudan sahiptir ve bu hisseler $ 9.07M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.4 yıl ve 7.5 yıldır.

Anahtar bilgiler

Rob Fried

İcra Kurulu Başkanı

US$1.2m

Toplam tazminat

CEO maaş yüzdesi	43.1%
CEO görev süresi	6.4yrs
CEO sahipliği	2.1%
Yönetim ortalama görev süresi	5.4yrs
Yönetim Kurulu ortalama görev süresi	7.5yrs

Son yönetim güncellemeleri

Shareholders Will Likely Find ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Acceptable

Jun 15

Recent updates

Revenues Tell The Story For ChromaDex Corporation (NASDAQ:CDXC) As Its Stock Soars 70%

Nov 05

ChromaDex Corporation (NASDAQ:CDXC) Stock Rockets 25% But Many Are Still Ignoring The Company

Jul 25

Shareholders Will Likely Find ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Acceptable

Jun 15

Positive Sentiment Still Eludes ChromaDex Corporation (NASDAQ:CDXC) Following 26% Share Price Slump

Jun 05

Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now?

Apr 05

Not Many Are Piling Into ChromaDex Corporation (NASDAQ:CDXC) Just Yet

Feb 28

ChromaDex Corporation's (NASDAQ:CDXC) Intrinsic Value Is Potentially 85% Above Its Share Price

Jan 29

Market Cool On ChromaDex Corporation's (NASDAQ:CDXC) Revenues

Jun 08

We're Hopeful That ChromaDex (NASDAQ:CDXC) Will Use Its Cash Wisely

Mar 31

ChromaDex inks new commercial supply agreement for its Niagen ingredient with Nestlé

Oct 11

ChromaDex wins patent challenge as US regulator rejects Thorne Research's demand to invalidate patent

Aug 15

CEO Tazminat Analizi

Rob Fried'un ücretlendirmesi ChromaDex'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$1m
Jun 30 2024	n/a	n/a	-US$1m
Mar 31 2024	n/a	n/a	-US$4m
Dec 31 2023	US$1m	US$500k	-US$5m
Sep 30 2023	n/a	n/a	-US$6m
Jun 30 2023	n/a	n/a	-US$6m
Mar 31 2023	n/a	n/a	-US$11m
Dec 31 2022	US$1m	US$500k	-US$17m
Sep 30 2022	n/a	n/a	-US$20m
Jun 30 2022	n/a	n/a	-US$28m
Mar 31 2022	n/a	n/a	-US$27m
Dec 31 2021	US$1m	US$500k	-US$27m
Sep 30 2021	n/a	n/a	-US$28m
Jun 30 2021	n/a	n/a	-US$23m
Mar 31 2021	n/a	n/a	-US$21m
Dec 31 2020	US$1m	US$519k	-US$20m
Sep 30 2020	n/a	n/a	-US$23m
Jun 30 2020	n/a	n/a	-US$26m
Mar 31 2020	n/a	n/a	-US$30m
Dec 31 2019	US$2m	US$487k	-US$32m
Sep 30 2019	n/a	n/a	-US$32m
Jun 30 2019	n/a	n/a	-US$33m
Mar 31 2019	n/a	n/a	-US$33m
Dec 31 2018	US$5m	US$379k	-US$33m
Sep 30 2018	n/a	n/a	-US$34m
Jun 30 2018	n/a	n/a	-US$29m
Mar 31 2018	n/a	n/a	-US$23m
Dec 30 2017	US$4m	US$231k	-US$17m

Tazminat ve Piyasa: Rob 'nin toplam tazminatı ($USD 1.16M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 2.40M ).

Tazminat ve Kazançlar: Rob 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Rob Fried (64 yo)

6.4yrs

Görev süresi

US$1,160,206

Tazminat

Mr. Robert N. Fried, also known as Rob, has been the Chief Executive Officer of ChromaDex Corp. since June 22, 2018 and its a Director since July 2015. Mr. Fried was the Chief Operating Officer of ChromaDe...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Frank Jaksch	Co-Founder & Chairman	24.8yrs	US$92.31k	3.01% $ 13.2m
Robert Fried	CEO & Director	6.4yrs	US$1.16m	2.06% $ 9.1m
Ozan Pamir	CFO & Principal Accounting Officer	less than a year	Veri yok	Veri yok
Andrew Shao	Senior Vice President of Global Regulatory & Scientific Affairs	4.8yrs	Veri yok	Veri yok
Carlos Lopez	Senior VP & General Counsel	less than a year	Veri yok	Veri yok
Alex Worsham	Vice President of Global Marketing & Communications	no data	Veri yok	Veri yok
Chu Yan	Managing Director of Asia Pacific	6.1yrs	Veri yok	Veri yok
Kendall Knysch	Head of Media Relations & Partnerships	no data	Veri yok	Veri yok
James Lee	Controller	no data	Veri yok	Veri yok

5.4yrs

Ortalama Görev Süresi

52.5yo

Ortalama Yaş

Deneyimli Yönetim: CDXC 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Frank Jaksch	Co-Founder & Chairman	24.8yrs	US$92.31k	3.01% $ 13.2m
Robert Fried	CEO & Director	9.3yrs	US$1.16m	2.06% $ 9.1m
Rudolph Tanzi	Member of Scientific Advisory Board	7.4yrs	Veri yok	Veri yok
Steven Rubin	Lead Independent Director	7.7yrs	US$117.31k	0.0091% $ 40.2k
Roger Kornberg	Chairman of the Scientific Advisory Board	10.3yrs	Veri yok	Veri yok
J. German	Member of Scientific Advisory Board	10.2yrs	Veri yok	Veri yok
Ann Cohen	Independent Director	2.6yrs	US$89.81k	0% $ 0
Wing Yu	Non-Executive Director	7.3yrs	US$67.31k	0% $ 0
Kristin Patrick	Independent Director	2.6yrs	US$82.31k	0% $ 0
Charles Brenner	Chief Scientific Advisor & Member of Scientific Advisory Board	10.2yrs	Veri yok	Veri yok
John Walker	Member of Scientific Advisory Board	6.5yrs	Veri yok	Veri yok
Brunie Felding	Member of the Scientific Advisory Board	5.3yrs	Veri yok	Veri yok

7.5yrs

Ortalama Görev Süresi

63.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CDXC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.5 yıldır).

ChromaDex Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Chromadex Corporation Announces Chief Financial Officer Changes

Independent Director notifies of intention to sell stock

ChromaDex Corporation Appoints Carlos Lopez as Senior Vice President, General Counsel

Shareholders Will Likely Find ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Acceptable

ChromaDex Corporation, Annual General Meeting, Jun 20, 2024

ChromaDex Appoints Dr. Vilhelm Bohr to Its Scientific Advisory Board

Recent updates

Revenues Tell The Story For ChromaDex Corporation (NASDAQ:CDXC) As Its Stock Soars 70%

ChromaDex Corporation Provides Earnings Guidance for the Full Year of 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

ChromaDex Corporation to Report Q3, 2024 Results on Oct 31, 2024

Chromadex Corporation Announces Chief Financial Officer Changes

Independent Director notifies of intention to sell stock

ChromaDex Corporation announced that it expects to receive $32.058489 million in funding

Price target increased by 7.6% to US$6.54

Forecast breakeven date moved forward to 2024

Second quarter 2024 earnings released: EPS: US$0 (vs US$0.029 loss in 2Q 2023)

ChromaDex Corporation Reiterates Earnings Guidance for the Full Year of 2024

ChromaDex Corporation (NASDAQ:CDXC) Stock Rockets 25% But Many Are Still Ignoring The Company

ChromaDex Corporation to Report Q2, 2024 Results on Aug 07, 2024

ChromaDex Corporation Appoints Carlos Lopez as Senior Vice President, General Counsel

ChromaDex Corp Shares Results from a Milestone Phase II Clinical Study Showing the Promising Effects of Nicotinamide Riboside (NR) Supplements for People with Peripheral Artery Disease

Shareholders Will Likely Find ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Acceptable

Chromadex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen®

Positive Sentiment Still Eludes ChromaDex Corporation (NASDAQ:CDXC) Following 26% Share Price Slump

New major risk - Share price stability

Consensus EPS estimates fall from profit to US$0.008 loss

ChromaDex Corporation Reiterates Earnings Guidance for the Full Year of 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 9.6% to US$6.28

ChromaDex Corporation, Annual General Meeting, Jun 20, 2024

ChromaDex Corporation to Report Q1, 2024 Results on May 08, 2024

Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now?

New minor risk - Share price stability

Consensus EPS estimates have been upgraded.

Price target increased by 13% to US$5.53

Price target decreased by 9.3% to US$4.94

Full year 2023 earnings: EPS exceeds analyst expectations

Not Many Are Piling Into ChromaDex Corporation (NASDAQ:CDXC) Just Yet

ChromaDex Corporation to Report Q4, 2023 Results on Mar 06, 2024

ChromaDex Corporation's (NASDAQ:CDXC) Intrinsic Value Is Potentially 85% Above Its Share Price

Neurohacker Collective and Chromadex Partner to Optimize Cellular Health with the Debut of Qualia Nad+

Ch ChromaDex Corp. shares results from a new breakthrough study analyzing the safety of high-dose nicotinamide riboside (NR) supplementation on individuals with Parkinson's disease (PD)

Chromadex Corp. Shares Results from Phase II Clinical Study

Consensus EPS estimates upgraded to US$0.088 loss

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

ChromaDex Corporation Provides Revenue Guidance for the Year 2023

Price target decreased by 11% to US$4.88

ChromaDex Corp. Debuts Clinical Strength Tru Niagen®? Pro 1,000Mg Featuring Niagen®? (Patented Nicotinamide Riboside)

ChromaDex Corporation to Report Q3, 2023 Results on Nov 08, 2023

ChromaDex Corp. and Zesty Paws Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line

New minor risk - Market cap size

Chromadex Announces Results from Newly Published Clinical Study, as Reported in the Peer-Reviewed Journal Cell Reports, Demonstrating That Supplementation with Nicotinamide Riboside

Consensus EPS estimates upgraded to US$0.12 loss

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

ChromaDex Corporation to Report Q2, 2023 Results on Aug 09, 2023

ChromaDex Corp. Announces Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD) in Glaucoma Patients and That Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects

Market Cool On ChromaDex Corporation's (NASDAQ:CDXC) Revenues

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ChromaDex Corporation Provides Revenue Guidance for the Full Year 2023

We're Hopeful That ChromaDex (NASDAQ:CDXC) Will Use Its Cash Wisely

Consensus EPS estimates fall by 24%

Full year 2022 earnings: EPS misses analyst expectations

ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients

ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis

ChromaDex Appoints Dr. Vilhelm Bohr to Its Scientific Advisory Board

Chromadex Corporation Names Brianna Gerber Chief Financial Officer

Forecast to breakeven in 2025

ChromaDex Corporation Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside Increase Nicotinamide Adenine Dinucleotide Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers

Chromadex Corp. Reports FDA’S Conclusion That Nicotinamide Mononucleotide (Nmn) May Not Be Sold or Marketed as A Dietary Supplement in the United States

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ChromaDex Corporation Provides Earnings Guidance for the Year 2022

ChromaDex Corporation to Report Q3, 2022 Results on Nov 02, 2022

ChromaDex inks new commercial supply agreement for its Niagen ingredient with Nestlé

Chromadex Shares Promising Findings from Clinical Study Showcasing The Safety and Tolerability of Nicotinamide Riboside (Nr) in Heart Failure with Reduced Ejection Fraction